香港股市 已收市

Becton, Dickinson and Company (BDX)

NYSE - NYSE 延遲價格。貨幣為 USD。
加入追蹤清單
247.54+2.37 (+0.97%)
收市價: 04:00PM EDT
247.54 0.00 (0.00%)
收市後: 07:06PM EDT

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800
https://www.bd.com

版塊Healthcare
行業Medical Instruments & Supplies
全職員工77,000

高階主管

名稱標題支付行使價出生年份
Mr. Thomas E. Polen Jr.Pres, CEO & Chairman3.93M1.89M1973
Mr. Christopher J. DelOreficeExec. VP & CFO1.99M1971
Ms. Shana Carol NealExec. VP & Chief People Officer1.44M1967
Mr. David B. HickeyExec. VP & Pres of Life Sciences Segment1.41M1963
Mr. Thomas J. SpoerelSr. VP, Controller & Chief Accounting Officer1978
Ms. Elizabeth McCombsExec. VP & Chief Technology Officer1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
Ms. Denise FlemingExec. VP of Technology & Global Services and Chief Information Officer
Ms. Francesca M. DeMartinoSr. VP & Head of Investor Relations
Ms. Michelle QuinnSr. VP and Chief Ethics & Compliance Officer and Acting Gen. Counsel1969
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

公司管治

截至 2023年2月1日 止,Becton, Dickinson and Company 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中:8;董事會:9;股東權利:9;現金賠償:10。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。